GlassScriptPhysician profile
Adam M Sabbath
NPI 1033155908
$1,828.59
in general payments reported to CMS, 2019-2025
21 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $87.43 · 2021: $113 · 2022: $145 · 2023: $247 · 2024: $81.51 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $590.39 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.90 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $191.37 | 2019-2020 | |
| Abbott Laboratories | $147.09 | 2019-2024 | Aveir, Cardiomems |
| Amgen INC. | $98.08 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $75.97 | 2022-2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $75.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.73 | 2019-2020 | |
| Boston Scientific Corporation | $39.58 | 2019-2022 | |
| Astellas Pharma US INC | $32.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.86 | 2022 | |
| Pfizer INC. | $29.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.57 | 2019-2020 | |
| Lundbeck LLC | $24.39 | 2019 | |
| Medtronic Vascular, INC. | $21.87 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.14 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $17.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2020 | |
| Amarin Pharma, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Sabbath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.